143 related articles for article (PubMed ID: 22086405)
41. Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Ben Nasr S; Zribi A; Ben Hassen M; Doghri Y; Ben Abdallah I; Trigui E; Fendri S; Ayari J; Balti M; Haddaoui A
Bull Cancer; 2021 Mar; 108(3):266-271. PubMed ID: 33423777
[TBL] [Abstract][Full Text] [Related]
42. Clinical picture: nail changes secondary to docetaxel.
Wasner G; Hilpert F; Baron R; Pfisterer J
Lancet; 2001 Mar; 357(9260):910. PubMed ID: 11289346
[No Abstract] [Full Text] [Related]
43. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.
Kenmotsu H; Tanigawara Y
Cancer Sci; 2015 May; 106(5):497-504. PubMed ID: 25728850
[TBL] [Abstract][Full Text] [Related]
45. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
46. A rare manifestation of nail changes with docetaxel therapy.
Halvorson CR; Erickson CL; Gaspari AA
Skinmed; 2010; 8(3):179-80. PubMed ID: 21137627
[TBL] [Abstract][Full Text] [Related]
47. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
[TBL] [Abstract][Full Text] [Related]
48. Docetaxel-induced nail changes--a neurogenic mechanism: a case report.
Wasner G; Hilpert F; Schattschneider J; Binder A; Pfisterer J; Baron R
J Neurooncol; 2002 Jun; 58(2):167-74. PubMed ID: 12164689
[TBL] [Abstract][Full Text] [Related]
49. Nail toxicity induced by cancer chemotherapy.
Gilbar P; Hain A; Peereboom VM
J Oncol Pharm Pract; 2009 Sep; 15(3):143-55. PubMed ID: 19171552
[TBL] [Abstract][Full Text] [Related]
50. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.
Poirier E; Desbiens C; Poirier B; Hogue JC; Lemieux J; Doyle C; Leblond AF; Côté I; Cantin G; Provencher L
Ann Pharmacother; 2014 Apr; 48(4):447-55. PubMed ID: 24321851
[TBL] [Abstract][Full Text] [Related]
51. Mild Cryotherapy for Prevention of Paclitaxel-Induced Nail Toxicity in Breast Cancer Patients: A Phase II Single-Arm Clinical Trial.
Mazzega-Fabbro C; Polesel J; Spazzapan S; Meneghetti L; Montagner D; Tabaro G; Bartoletti M; Puglisi F
Clin Breast Cancer; 2023 Jun; 23(4):447-453. PubMed ID: 36997403
[TBL] [Abstract][Full Text] [Related]
52. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P; Barrett-Lee P; Johnson L; Cameron D; Wardley A; O'Reilly S; Verrill M; Smith I; Yarnold J; Coleman R; Earl H; Canney P; Twelves C; Poole C; Bloomfield D; Hopwood P; Johnston S; Dowsett M; Bartlett JM; Ellis I; Peckitt C; Hall E; Bliss JM; ;
Lancet; 2009 May; 373(9676):1681-92. PubMed ID: 19447249
[TBL] [Abstract][Full Text] [Related]
53. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Cox MC; Low J; Lee J; Walshe J; Denduluri N; Berman A; Permenter MG; Petros WP; Price DK; Figg WD; Sparreboom A; Swain SM
Clin Cancer Res; 2006 Aug; 12(15):4636-40. PubMed ID: 16899612
[TBL] [Abstract][Full Text] [Related]
54. Nail changes during docetaxel containing combination chemotherapy.
Woo IS; Shim KH; Kim GY; Lee MA; Kang JH; Hong YS; Lee KS
Korean J Intern Med; 2004 Jun; 19(2):132-3. PubMed ID: 15366647
[TBL] [Abstract][Full Text] [Related]
55. Severe nail changes due to Docetaxel treatment.
Rafi L; Friedrich M; Tilgen W; Reichrath J
Eur J Dermatol; 2003; 13(6):610-1. PubMed ID: 14721789
[TBL] [Abstract][Full Text] [Related]
56. Trastuzumab/docetaxel-induced nail dystrophy.
Alexandrescu DT; Vaillant J; Wiernik PH
Int J Dermatol; 2006 Nov; 45(11):1334-6. PubMed ID: 17076719
[No Abstract] [Full Text] [Related]
57. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
[TBL] [Abstract][Full Text] [Related]
58. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Warm M; Nawroth F; Ohlinger R; Valter M; Pantke E; Mallmann P; Harbeck N; Kates R; Thomas A
Onkologie; 2007 Sep; 30(8-9):436-41. PubMed ID: 17848815
[TBL] [Abstract][Full Text] [Related]
59. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
60. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
Kim JY; Ok ON; Seo JJ; Lee SH; Ahn JS; Im YH; Park YH
Breast Cancer Res Treat; 2017 Aug; 164(3):617-625. PubMed ID: 28488142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
